Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.

Autor: Allen JL; Program in Cancer Cell Biology, Department of Biochemistry, West Virginia University, Morgantown, WV, 26506, United States., Hames RA; Program in Cancer Cell Biology, Department of Biochemistry, West Virginia University, Morgantown, WV, 26506, United States., Mastroianni NM; Program in Cancer Cell Biology, Department of Biochemistry, West Virginia University, Morgantown, WV, 26506, United States., Greenstein AE; Gilead Sciences, Inc., Foster City, CA 94404, United States., Weed SA; Program in Cancer Cell Biology, Department of Biochemistry, West Virginia University, Morgantown, WV, 26506, United States. Electronic address: scweed@hsc.wvu.edu.

Publikováno v: Oral oncology [Oral Oncol] 2022 Sep; Vol. 132, pp. 106008. Date of Electronic Publication: 2022 Jul 06.